Instil Bio, Inc. Payments to Acquire Debt Securities, Available-for-sale
Instil Bio, Inc. (TIL) reported Payments to Acquire Debt Securities, Available-for-sale of $39.83 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt · last filed 2026-08-13
- Instil Bio, Inc. payments to acquire debt securities, available-for-sale for the quarter ending 2026-06-30 was $17.51M, a 54.77% decline year-over-year.
- Instil Bio, Inc. payments to acquire debt securities, available-for-sale for the quarter ending 2026-03-31 was $22.32M, a 41.57% decline year-over-year.
- Instil Bio, Inc. payments to acquire debt securities, available-for-sale for the quarter ending 2025-12-31 was $17.39M, a 36.35% decline year-over-year.
- Instil Bio, Inc. payments to acquire debt securities, available-for-sale for the quarter ending 2025-09-30 was $6.56M, a 57.97% decline year-over-year.
- Instil Bio, Inc. payments to acquire debt securities, available-for-sale for fiscal 2025 was $100.86M, a 24.74% decline from fiscal 2024.
- Instil Bio, Inc. payments to acquire debt securities, available-for-sale for fiscal 2024 was $134.01M, a 55.55% decline from fiscal 2023.
- Instil Bio, Inc. payments to acquire debt securities, available-for-sale for fiscal 2023 was $301.47M, a 54.67% decline from fiscal 2022.
- Instil Bio, Inc. payments to acquire debt securities, available-for-sale for fiscal 2022 was $665.05M, a 39.95% decline from fiscal 2021.
| Period end | Payments to Acquire Debt Securities, Available-for-sale 3 month | Payments to Acquire Debt Securities, Available-for-sale 6 month | Payments to Acquire Debt Securities, Available-for-sale 9 month | Payments to Acquire Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|
| 2026-06-30 | $17.51M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $39.83M 10-Q · filed 2026-08-13 | $57.22M derived: sum of 3 quarters · filed 2026-08-13 | $63.77M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $22.32M 10-Q · filed 2026-05-15 | $39.71M derived: sum of 2 quarters · filed 2026-05-15 | $46.27M derived: sum of 3 quarters · filed 2026-05-15 | $84.98M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $17.39M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $23.95M derived: sum of 2 quarters · filed 2026-03-27 | $62.66M derived: sum of 3 quarters · filed 2026-08-13 | $100.86M 10-K · filed 2026-03-27 |
| 2025-09-30 | $6.56M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $45.27M derived: sum of 2 quarters · filed 2026-08-13 | $83.47M 10-Q · filed 2025-11-13 | $110.79M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $38.71M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $76.91M 10-Q · filed 2026-08-13 | $104.23M derived: sum of 3 quarters · filed 2026-08-13 | $119.83M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $38.19M 10-Q · filed 2026-05-15 | $65.52M derived: sum of 2 quarters · filed 2026-05-15 | $81.12M derived: sum of 3 quarters · filed 2026-05-15 | $121.55M derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | $27.32M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $42.93M derived: sum of 2 quarters · filed 2026-03-27 | $83.35M derived: sum of 3 quarters · filed 2026-03-27 | $134.01M 10-K · filed 2026-03-27 |
| 2024-09-30 | $15.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $56.03M derived: sum of 2 quarters · filed 2025-11-13 | $106.68M 10-Q · filed 2025-11-13 | $157.63M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $40.42M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $91.08M 10-Q · filed 2025-08-13 | $142.03M derived: sum of 3 quarters · filed 2025-08-13 | $214.05M derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | $50.66M 10-Q · filed 2025-05-13 | $101.61M derived: sum of 2 quarters · filed 2025-05-13 | $173.63M derived: sum of 3 quarters · filed 2025-05-13 | $270.12M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $50.95M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-04 | $122.97M derived: sum of 2 quarters · filed 2025-03-04 | $219.46M derived: sum of 3 quarters · filed 2025-03-04 | $301.47M 10-K · filed 2025-03-04 |
| 2023-09-30 | $72.02M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $168.51M derived: sum of 2 quarters · filed 2024-11-13 | $250.52M 10-Q · filed 2024-11-13 | $359.05M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | $96.49M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $178.49M 10-Q · filed 2024-08-13 | $287.03M derived: sum of 3 quarters · filed 2024-08-13 | $371.46M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | $82.00M 10-Q · filed 2024-05-10 | $190.54M derived: sum of 2 quarters · filed 2024-05-10 | $274.97M derived: sum of 3 quarters · filed 2024-05-10 | $494.65M derived: sum of 4 quarters · filed 2024-05-10 |
| 2022-12-31 | $108.54M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | $192.96M derived: sum of 2 quarters · filed 2024-03-21 | $412.65M derived: sum of 3 quarters · filed 2024-03-21 | $665.05M 10-K · filed 2024-03-21 |
| 2022-09-30 | $84.43M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $304.11M derived: sum of 2 quarters · filed 2023-11-13 | $556.51M 10-Q · filed 2023-11-13 | $964.09M derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | $219.68M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $472.08M 10-Q · filed 2023-08-14 | $879.66M derived: sum of 3 quarters · filed 2023-08-14 | $1.58B derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | $252.40M 10-Q · filed 2023-05-11 | $659.98M derived: sum of 2 quarters · filed 2023-05-11 | $1.36B derived: sum of 3 quarters · filed 2023-05-11 | $1.36B derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $407.58M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $1.11B derived: sum of 2 quarters · filed 2023-03-31 | $1.11B derived: sum of 3 quarters · filed 2023-03-31 | $1.11B 10-K · filed 2023-03-31 |
| 2021-09-30 | $699.99M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $699.99M derived: sum of 2 quarters · filed 2022-11-14 | $699.99M 10-Q · filed 2022-11-14 | $699.99M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-12 | $0.00 10-Q · filed 2022-08-12 | $0.00 derived: sum of 3 quarters · filed 2022-08-12 | |
| 2021-03-31 | $0.00 10-Q · filed 2022-05-16 | $0.00 derived: sum of 2 quarters · filed 2022-05-16 | ||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-07 | $0.00 10-K · filed 2022-03-07 | ||
| 2020-09-30 | $0.00 10-Q · filed 2021-11-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |